ADVANCES
gMG disease dialogues:
clinical advances and expert insights

Join Dr. Kelly Gwathmey in conversation with each episode’s topic expert, in this five-part accredited video podcast series. Together, they explore the latest clinical breakthroughs, emerging data, and practical insights in the management of generalized myasthenia gravis (gMG).
Whether you’re looking to stay current or deepen your clinical understanding, this series delivers expert insights designed for healthcare professionals. Tune in now to stay ahead in your field.
Episode 1 | Understanding gMG
Dr. Kelly Gwathmey, MD
Dr. Sithara Ramdas, MD
-
0.25 AMA PRA Category 1 Credits™ available
Expiry: June 9, 2026
- Activity time: 20 min
Episode 2, part 1 | New and emerging therapies in gMG: FcRn receptor antagonists and complement inhibition
Dr. Kelly Gwathmey, MD
Dr. Pushpa Naranayaswami, MD, FAAN
-
0.25 AMA PRA Category 1 Credits™ available
Expiry: June 16, 2026
- Activity time: 25 min
Episode 2, part 2 | New and emerging therapies in gMG: going upstream, T-cell and B-cell targeted therapies
Dr. Kelly Gwathmey, MD
Dr. Pushpa Naranayaswami, MD, FAAN
-
0.25 AMA PRA Category 1 Credits™ available
Expiry: June 16, 2026
- Activity time: 25 min
Episode 3 | Advances in gMG: implications for practice
Dr. Kelly Gwathmey, MD
Dr. Sithara Ramdas, MD
-
0.25 AMA PRA Category 1 Credits™ available
- Activity time: 20 min
Episode 4 | Embracing gMG advances together: ensuring multidisciplinary collaboration
Dr. Kelly Gwathmey, MD
Jude Kings, RGN
-
0.25 AMA PRA Category 1 Credits™ available
- Activity time: 25 min
Pressed for time?
Tune in to the audio version of this expert podcast on Spotify, Apple Podcasts, or your favorite podcast platform. Anytime, Anywhere!
Meet the experts

Dr. Kelly Gwathmey, MD
Virginia Commonwealth University
Virginia Commonwealth University
Richmond, VA,
United States
Kelly Gwathmey is originally from Richmond, Virginia. She studied neuroscience and behavioral biology at Emory University in Atlanta, Georgia. She then attended Eastern Virginia Medical School in Norfolk, Virginia. Her neurology and clinical neurophysiology training was completed at the University of Virginia. Following this, she completed a neuromuscular medicine fellowship at both Brigham and Women’s Hospital and Massachusetts General Hospital in Boston, Massachusetts. At the University of Virginia, she started the multidisciplinary MDA clinic, was co-director of the ALS clinic, and was the fellowship director for both the neuromuscular and clinical neurophysiology fellowships. She joined Virginia Commonwealth University in January 2019 and currently serves in the capacity of associate professor of neurology, neuromuscular division chair, neuromuscular medicine program director, and EMG laboratory director. Dr. Gwathmey sees a wide spectrum of neuromuscular patients and performs electrodiagnostic studies (nerve conduction studies and electromyography). Her research interests include quality-of-life instruments and autoimmune neuromuscular disorders.
Disclosures
Speakers Bureau/honoraria for non-CME: Alexion pharmaceuticals, argenx
Consultant/advisory board: Alexion pharmaceuticals, Amgen, argenx, UCB

Dr. Pushpa Narayanaswami, MD, FAAN
Beth Israel Deaconess Medical Center / Harvard Medical School
Boston, MA, United States

Dr. Pushpa Narayanaswami, MD, FAAN
Beth Israel Deaconess Medical Center / Harvard Medical School
Beth Israel Deaconess Medical Center / Harvard Medical School
Boston, MA,
United States
Pushpa Narayanaswami is Professor of Clinical Neurology at Harvard Medical School and Vice-Chair of Clinical Operations, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA. She is a fellow of the American Academy of Neurology (AAN). She has authored/co-authored several peer-reviewed articles, invited reviews, editorials, clinical practice guidelines, quality measures, book chapters and edited a book, “Principles and Practice of the Muscular Dystrophies”. She has received federal research funding from the Agency for Healthcare Research and Quality (AHRQ), Patient Centered Outcomes Research Institute (PCORI) and National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). She serves as an associate editor for Muscle & Nerve and as the associate editor, classification of evidence, for Neurology® Journals. She co-chairs the Quality Improvement and Patient Safety Committee of the American Association of Neuromuscular and Electrodiagnostic Medicine.
In her clinical practice she manages neuromuscular conditions, with special emphasis on myasthenia gravis, myopathies and muscular dystrophies. Her research includes clinical trials of new treatments for myasthenia gravis and observational studies of the effectiveness of treatments in clinical practice. She is a methodologist for several guidelines in development. Her work seeks to incorporate research with advocacy and healthcare policy to improve patient care.
Disclosures
Grant/research support: Alexion, Cabaletta Bio, Dianthus, NIAMS, PCORI
Consultant/advisory board: Alexion. argenx, Amgen, CVS Healthcare, Dianthus, ImmunAbs, Janssen, Merck-Serono, Roche, UCB
Non-mutual funds stock ownership/stock options: Dr. Reddy’s Laboratories, Moderna, Pfizer
Patent holder/royalties: Springer-Nature book royalty
Other financial or material support:
-
Data and safety monitoring board member: argenx, Sanofi, NMD Pharma
- Associate editor: Muscle & Nerve and Neurology® Journals

Dr. Sithara Ramdas, MD
Oxford Children's Hospital
Oxford Children’s Hospital
Oxford,
United Kingdom
Sithara Ramdas is a Consultant Paediatric Neurologist based at the Oxford Children’s Hospital and an Honorary Senior Clinical Lecturer with the University of Oxford. Her specialist interests are neuromuscular disorders and neuroimmunology. She leads the regional Paediatric Neuromuscular multi-disciplinary service. She is the Paediatric lead for the National Highly Specialised Services for Congenital Myasthenia Syndromes and Neuromyelitis Optica. She leads the Highly Specialised Service for Paediatric Multiple Sclerosis and NHS England Rare Disease Collaborative Network (RDCN) for Juvenile Myasthenia Gravis. She is the principal investigator for several past and current clinical trials and her current areas of research interest are on Duchenne muscular dystrophy (DMD), spinal muscular atrophy (SMA), Congenital and Acquired Myasthenia.
Disclosures
Speakers bureau/honoraria for non-CME: Roche
Consultant/advisory board: Italfarmaco, Pfizer, Roche
Educational grants: Biogen, Novartis, Roche

Jude Kings, RGN
Wessex Neurological Centre
Southampton General Hospital, Southampton, United Kingdom

Jude Kings, RGN
Wessex Neurological Centre
Myasthenia Specialist Nurse,
Wessex Neurological Centre
Southampton General Hospital, Southampton,
United Kingdom
Jude Kings is a myasthenia gravis specialist nurse at the Wessex Neurological Centre, Southampton General Hospital, Southampton, UK. She has a Bachelor of Science in Adult Nursing from Oxford Brookes University, and has specialised in neurology since 2001. Jude has worked in various clinical settings including in-patient neuro rehabilitation and other specialist nursing roles within the community for stoke and complex neurology patients. She is a non-medical independent prescriber. Alongside her current role as MG Specialist Nurse, she is a member of the global Nurse steering committee for MG, in conjunction with UCB Pharma Ltd, and co-author on a publication on the role of MG Clinical Nurse Specialist role and the use of personal health records in neurology. Ms. Kings has also been involved in the development of elearning training modules for nurses in NM/MG (neurology academy) and have presented at the RCDN Rare Disease Connect in Neurology conferences on the role of MG Specialist nurse and decision making in practice.
Disclosures
Speakers bureau/honoraria for non-CME: argenx Pharma, Neurology Academy, UCB Pharma Ltd
Available now:
Voices of gMG video
module

Visit the AWARENESS phase, a compelling patient-physician conversation between Janel and Dr. Gwathmey which yields insights into the lived experiences of patients with gMG and the challenges they face navigating their healthcare journey.
Arriving in June 2025:
your ready-to-use toolkit!
Don’t miss out on our upcoming ACTION phase, a downloadable and printable toolkit of strategies and resources. Expert-authored clinical practice aids and patient guides, to optimize your patient care.
Accreditation

In support of improving patient care, these activities have been planned and implemented by the Postgraduate Institute for Medicine and Springer Healthcare IME. The Postgraduate Insititute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activities.